targeted protein degradation

WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...

WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...

BOSTON and DAEJEON, South Korea, Jan. 4, 2026 — Orum Therapeutics, a biotechnology company pioneering degrader-antibody conjugates (DACs), announced...

BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...